{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:51:06Z","timestamp":1770727866867,"version":"3.49.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.schres.2022.07.007","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T17:43:11Z","timestamp":1658511791000},"page":"277-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic na\u00efve patients with first-episode psychosis: Baseline results from the PAFIP cohort"],"prefix":"10.1016","volume":"246","author":[{"given":"Nathalia","family":"Garrido-Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Ruiz-Veguilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Alameda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Canal-Rivero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Juncal","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"G\u00f3mez-Revuelta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Ayesa-Arriola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Rubio-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"V\u00e1zquez-Bourgon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2022.07.007_bb0005","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.bbi.2017.06.005","article-title":"Childhood maltreatment severity is associated with elevated C-reactive protein and body mass index in adults with schizophrenia and bipolar diagnoses","volume":"65","author":"Aas","year":"2017","journal-title":"Brain Behav. Immun."},{"issue":"12","key":"10.1016\/j.schres.2022.07.007_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242569","article-title":"Psychological trauma occurring during adolescence is associated with an increased risk of greater waist circumference in early psychosis patients treated with psychotropic medication","volume":"15","author":"Alameda","year":"2020","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.schres.2022.07.007_bb0015","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.schres.2022.07.007_bb0380","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/2047487319848214","article-title":"HDL: fact, fiction, or function? HDL cholesterol and cardiovascular risk","volume":"28","author":"Allard-Ratick","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"7","key":"10.1016\/j.schres.2022.07.007_bb0020","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00406-012-0302-2","article-title":"Homocysteine and cognition in first-episode psychosis patients","volume":"262","author":"Ayesa-Arriola","year":"2012","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2022.07.007_bb0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.dsx.2013.10.003","article-title":"A two fold risk of metabolic syndrome in a sample of patients with schizophrenia: do consanguinity and family history increase risk?","volume":"8","author":"Bener","year":"2014","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.schres.2022.07.007_bb0030","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.schres.2020.06.011","article-title":"Predictors of weight acquisition induced by antipsychotic treatment and its relationship with age in a sample of first episode non-affective psychosis patients: a three-year follow-up study","volume":"222","author":"Canal-Rivero","year":"2020","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2022.07.007_bb0035","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.eurpsy.2014.11.013","article-title":"Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic","volume":"30","author":"Chiliza","year":"2015","journal-title":"Eur. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2022.07.007_bb0040","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4093\/dmj.2018.0039","article-title":"The risk of myocardial infarction and ischemic stroke according to waist circumference in 21,749,261 Korean adults: a nationwide population-based study","volume":"43","author":"Cho","year":"2019","journal-title":"Diabetes Metab. J."},{"issue":"12","key":"10.1016\/j.schres.2022.07.007_bb0045","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","article-title":"Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study","volume":"71","author":"Correll","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2022.07.007_bb0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2022.07.007_bb0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.schres.2020.03.071","article-title":"Chronic smoking and cognition in patients with schizophrenia: a meta- analysis","volume":"222","author":"Coustals","year":"2020","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.07.007_bb0060","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2008.01.028","article-title":"Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review","volume":"101","author":"De Hert","year":"2008","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2022.07.007_bb0065","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/acps.12880","article-title":"Natural cause mortality in persons with serious mental illness","volume":"137","author":"Dickerson","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"issue":"9468","key":"10.1016\/j.schres.2022.07.007_bb0070","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.schres.2022.07.007_bb0075","first-page":"48","article-title":"Metabolic syndrome in a sample of drug-naive egyptian patients with psychotic disorders","volume":"15","author":"Effat","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.07.007_bb0080","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2015.05.004","article-title":"Metabolic syndrome in drug-na\u00efve and drug-free patients with schizophrenia and in their siblings","volume":"166","author":"Enez Darcin","year":"2015","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.07.007_bb0085","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2015.05.004","article-title":"Metabolic syndrome in drug-na\u00efve and drug-free patients with schizophrenia and in their siblings","volume":"166","author":"Enez Darcin","year":"2015","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2022.07.007_bb0090","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/mp.2015.87","article-title":"C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications","volume":"21","author":"Fernandes","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2022.07.007_bb0415","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1192\/bjp.bp.108.052605","article-title":"Metabolic profile of antipsychotic-naive individuals with non-affective psychosis","volume":"194","author":"Fernandez-Egea","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2022.07.007_bb0395","series-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition","author":"First","year":"2002"},{"issue":"5","key":"10.1016\/j.schres.2022.07.007_bb0095","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1017\/S1461145712001241","article-title":"Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial","volume":"16","author":"Fleischhacker","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2022.07.007_bb0410","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eurpsy.2016.10.001","article-title":"Metabolic syndrome or glucose challenge in first episode of psychosis?","volume":"41","author":"Garcia-Rizo","year":"2017","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2022.07.007_bb0100","article-title":"Metabolic syndrome in antipsychotic-naive patients with first-episode psychosis: a systematic review and meta-analysis","volume":"1\u201314","author":"Garrido-Torres","year":"2021","journal-title":"Psychol. Med."},{"issue":"3","key":"10.1016\/j.schres.2022.07.007_bb0105","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1751-7893.2011.00321.x","article-title":"Metabolic syndrome in antipsychotic na\u00efve patients diagnosed with schizophrenia","volume":"6","author":"Grover","year":"2012","journal-title":"Early Interv. Psychiatry"},{"issue":"17","key":"10.1016\/j.schres.2022.07.007_bb0110","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.schres.2022.07.007_bb0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/clc.22533","article-title":"Association between very low levels of high-density lipoprotein cholesterol and long-term outcomes of patients with acute coronary syndrome treated without revascularization: insights from the TRILOGY ACS trial","volume":"39","author":"Hagstrom","year":"2016","journal-title":"Clin. Cardiol."},{"issue":"5\u20136","key":"10.1016\/j.schres.2022.07.007_bb0120","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1242\/dmm.001180","article-title":"A comprehensive definition for metabolic syndrome","volume":"2","author":"Huang","year":"2009","journal-title":"Dis. Model. Mech."},{"issue":"4","key":"10.1016\/j.schres.2022.07.007_bb0125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1600-0447.2009.01401.x","article-title":"Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan","volume":"120","author":"Huang","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"issue":"6","key":"10.1016\/j.schres.2022.07.007_bb0390","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/YPG.0000000000000181","article-title":"Genetic variants of increased waist circumference in psychosis","volume":"27","author":"Hukic","year":"2017","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.schres.2022.07.007_bb0130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.schres.2018.03.016","article-title":"Dietary patterns and physical activity in people with schizophrenia and increased waist circumference","volume":"199","author":"Jakobsen","year":"2018","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.schres.2022.07.007_bb0405","doi-asserted-by":"crossref","first-page":"e1035","DOI":"10.4088\/JCP.15m10479","article-title":"Pretreatment cardiometabolic status in youth with early-onset psychosis: baseline results from the TEA trial","volume":"78","author":"Jensen","year":"2017","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2022.07.007_bb0135","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2337\/diacare.28.9.2289","article-title":"The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"28","author":"Kahn","year":"2005","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.schres.2022.07.007_bb0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3371\/CSRP.KIMI.031513","article-title":"Schizophrenia: a systemic disorder","volume":"8","author":"Kirkpatrick","year":"2014","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"issue":"2","key":"10.1016\/j.schres.2022.07.007_bb0145","first-page":"8","article-title":"Sex differences in antipsychotic related metabolic functioning in schizophrenia spectrum disorders","volume":"47","author":"Kraal","year":"2017","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.schres.2022.07.007_bb0150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1471-244X-11-173","article-title":"Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics\u2014results from a german observational study","volume":"11","author":"Kraemer","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2022.07.007_bb0155","series-title":"A Comprehensive Tool for Validated Entry and Documentation of Data","author":"Lauritsen","year":"2004"},{"issue":"2","key":"10.1016\/j.schres.2022.07.007_bb0160","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/YCO.0b013e32835035ca","article-title":"Life expectancy and cardiovascular mortality in persons with schizophrenia","volume":"25","author":"Laursen","year":"2012","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.schres.2022.07.007_bb0425","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eurpsy.2010.08.011","article-title":"A four-year naturalistic prospective study of cardiometabolic disease in antipsychotic-treated patients","volume":"27","author":"Mackin","year":"2012","journal-title":"Eur. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2022.07.007_bb0165","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.rpsm.2012.04.001","article-title":"After six months of anti-psychotic treatment: is the improvement in mental health at the expense of physical health?","volume":"6","author":"Mart\u00edn Ota\u00f1o","year":"2013","journal-title":"Revista de psiquiatria y salud mental"},{"issue":"9","key":"10.1016\/j.schres.2022.07.007_bb0170","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00392-017-1106-1","article-title":"HDL cholesterol: reappraisal of its clinical relevance","volume":"106","author":"Marz","year":"2017","journal-title":"Clin. Res. Cardiol."},{"issue":"8","key":"10.1016\/j.schres.2022.07.007_bb0175","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/0269881108093927","article-title":"Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up","volume":"23","author":"Medved","year":"2009","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2022.07.007_bb0180","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s11011-014-9534-3","article-title":"Elevated homocysteine level in first-episode schizophrenia patients\u2014the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse","volume":"29","author":"Misiak","year":"2014","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.schres.2022.07.007_bb0185","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2017.03.031","article-title":"Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: a systematic review and meta-analysis","volume":"190","author":"Misiak","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2022.07.007_bb0190","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.neubiorev.2019.05.018","article-title":"Appetite regulating hormones in first-episode psychosis: a systematic review and meta-analysis","volume":"102","author":"Misiak","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"10.1016\/j.schres.2022.07.007_bb0195","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/schbul\/sbs082","article-title":"Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2022.07.007_bb0200","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2014a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2022.07.007_bb0205","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.5888\/pcd14.160287","article-title":"Metabolic syndrome prevalence by Race\/Ethnicity and sex in the United States, National Health and nutrition examination survey, 1988\u20132012","volume":"14","author":"Moore","year":"2017","journal-title":"Prev. Chronic Dis."},{"issue":"2","key":"10.1016\/j.schres.2022.07.007_bb0210","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jamapsychiatry.2014.2133","article-title":"Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program","volume":"72","author":"Osborn","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2022.07.007_bb0215","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08039488.2013.797022","article-title":"Psychotic disorder is an independent risk factor for increased fasting glucose and waist circumference","volume":"68","author":"Osby","year":"2014","journal-title":"Nordic J Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2022.07.007_bb0220","first-page":"38","article-title":"Prevalence of metabolic syndrome among Psychiatric Patients in the Kumasi Metropolis, Ghana","volume":"1","author":"Owiredu","year":"2012","journal-title":"En J. Med. Biomed. Sci."},{"issue":"3","key":"10.1016\/j.schres.2022.07.007_bb0225","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/08039488.2011.621977","article-title":"Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free\/na\u00efve and antipsychotic-treated patients from India","volume":"66","author":"Pallava","year":"2012","journal-title":"Nordic J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2022.07.007_bb0400","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1751-7893.2008.00074.x","article-title":"Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis","volume":"2","author":"Pelayo-Ter\u00e1n","year":"2008","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.schres.2022.07.007_bb0230","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eurpsy.2016.02.004","article-title":"Cardiovascular risk factors among patients with schizophrenia, bipolar, depressive, anxiety, and personality disorders","volume":"35","author":"Perez-Pinar","year":"2016","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2022.07.007_bb0235","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.schres.2017.03.046","article-title":"Letter to the editor: Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis","volume":"192","author":"Perry","year":"2018","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.schres.2022.07.007_bb0240","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S2215-0366(16)30262-0","article-title":"The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis","volume":"3","author":"Perry","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2022.07.007_bb0245","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/acps.13212","article-title":"Cardiometabolic risk prediction algorithms for young people with psychosis: a systematic review and exploratory analysis","volume":"142","author":"Perry","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.schres.2022.07.007_bb0250","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jamapsychiatry.2016.3803","article-title":"Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis","volume":"74","author":"Pillinger","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2022.07.007_bb0255","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1192\/bjp.bp.117.200907","article-title":"Cholesterol and triiglyceride levels first-episode psychosis systematic review and meta analysis","volume":"211","author":"Pillinger","year":"2017","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2022.07.007_bb0260","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sby018.806","article-title":"S19. Evidence of the lipid paradox in psychosis: a META-analysis of cholesterol and triglyceride levels in FIRST episode psychosis","volume":"44","author":"Pillinger","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.schres.2022.07.007_bb0265","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41380-018-0058-9","article-title":"Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models","volume":"24","author":"Pillinger","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2022.07.007_bb0270","article-title":"Higher prevalence of metabolic syndrome and related factors in patients with first-episode psychosis and schizophrenia: a cross-sectional study in Turkey","volume":"1\u20136","author":"Sahpolat","year":"2020","journal-title":"Nordic J. Psychiatry"},{"key":"10.1016\/j.schres.2022.07.007_bb0275","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.atherosclerosis.2017.08.032","article-title":"Association of high-density lipoprotein cholesterol concentration with different types of stroke and coronary heart disease: the Japan public health center-based prospective (JPHC) study","volume":"265","author":"Saito","year":"2017","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.schres.2022.07.007_bb0280","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1177\/0003319713502253","article-title":"High-density lipoproteins and coronary artery disease: a single-center cohort study","volume":"65","author":"Schaffer","year":"2014","journal-title":"Angiology"},{"issue":"1","key":"10.1016\/j.schres.2022.07.007_bb0285","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12872-021-02000-x","article-title":"The association between homocysteine levels and cardiovascular disease risk among middle-aged and elderly adults in Taiwan","volume":"21","author":"Shih","year":"2021","journal-title":"BMC Cardiovasc. Disord."},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.07.007_bb0290","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.schres.2013.01.014","article-title":"Cardiovascular mortality in schizophrenia: defining a critical period for prevention","volume":"146","author":"Srihari","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2022.07.007_bb0295","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ajp.2018.02.009","article-title":"Comparative study of quality of life and metabolic syndrome in schizophrenia patients who are receiving treatment versus antipsychotic na\u00efve, first episode patients from a tertiary care hospital","volume":"31","author":"Srivastava","year":"2018","journal-title":"Asian J. Psychiatr."},{"issue":"2","key":"10.1016\/j.schres.2022.07.007_bb0300","first-page":"363","article-title":"Innate immune cells and C-reactive protein in acute first-episode psychosis and schizophrenia: relationship to psychopathology and treatment","volume":"46","author":"Steiner","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2022.07.007_bb0305","article-title":"Cannabis use and metabolic syndrome among clients with first episode psychosis","author":"Stiles","year":"2020","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.schres.2022.07.007_bb0310","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.schres.2021.08.022","article-title":"Increased rates of respiratory disease in schizophrenia: a systematic review and meta-analysis including 619,214 individuals with schizophrenia and 52,159,551 controls","volume":"237","author":"Suetani","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2022.07.007_bb0385","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2147\/NDT.S269619","article-title":"Predictive utility of body mass index for metabolic syndrome among patients with schizophrenia in Japan","volume":"16","author":"Sugawara","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.schres.2022.07.007_bb0315","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00213-020-05727-1","article-title":"Prevalence of obesity and clinical and metabolic correlates in first- episode schizophrenia relative to healthy controls","volume":"238","author":"Tian","year":"2021","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.schres.2022.07.007_bb0320","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/00048670701392841","article-title":"Obesity and metabolic syndrome in a psychiatric rehabilitation service","volume":"41","author":"Tirupati","year":"2007","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2022.07.007_bb0325","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"issue":"S","key":"10.1016\/j.schres.2022.07.007_bb0330","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1016\/j.eurpsy.2017.02.431","article-title":"Long-term metabolic effect of second-generation antipsychotics in first episode of psychosis","volume":"41","author":"Vazquez Bourgon","year":"2017","journal-title":"Eur. P"},{"issue":"1","key":"10.1016\/j.schres.2022.07.007_bb0335","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-017-4763-x","article-title":"Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naive patients with a first-episode of non-affective psychosis","volume":"235","author":"Vazquez-Bourgon","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2022.07.007_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.dib.2019.104415","article-title":"Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis","volume":"27","author":"Vazquez-Bourgon","year":"2019","journal-title":"Data in Brief"},{"issue":"3","key":"10.1016\/j.schres.2022.07.007_bb0345","first-page":"284","article-title":"Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study","volume":"33","author":"Vazquez-Bourgon","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2022.07.007_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2020.08.009","article-title":"A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: a pragmaticclinical trial in first episode psychosis patients","author":"Vazquez-Bourgon","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2022.07.007_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyaa066","article-title":"Treatment discontinuation impact on long-term (10-year) weight gain and lipid metabolism in first-episode psychosis: results from the PAFIP-10 cohort","volume":"24","author":"V\u00e1zquez-Bourgon","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2022.07.007_bb0355","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.amjmed.2015.10.019","article-title":"Metabolic syndrome among marijuana users in the United States: an analysis of National Health and nutrition examination survey data","volume":"129","author":"Vidot","year":"2016","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.schres.2022.07.007_bb0360","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","article-title":"Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis","volume":"72","author":"Walker","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2022.07.007_bb0365","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41398-020-0717-x","article-title":"Sex differences in the association of body mass index with symptoms and cognitive deficits in chinese patients with chronic schizophrenia","volume":"10","author":"Wei","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2022.07.007_bb0370","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2174\/1381612822666161027153140","article-title":"HDL-targeting therapeutics: past, present and future","volume":"23","author":"Zakiev","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.schres.2022.07.007_bb0375","article-title":"Unveiling the metabolic profile of first-episode drug-naive schizophrenia patients: baseline characteristics of a longitudinal study among Han Chinese","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996422002791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996422002791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:50:32Z","timestamp":1760298632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996422002791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":85,"alternative-id":["S0920996422002791"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2022.07.007","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic na\u00efve patients with first-episode psychosis: Baseline results from the PAFIP cohort","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2022.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}